Eton Pharmaceuticals Inc (ETON) has a regulatory event to watch this week related to its investigational drug ET-600, a proprietary, patented formulation of desmopressin oral solution.
ET-600 is proposed for the treatment of central diabetes insipidius, also known as arginine vasopressin deficiency, with the FDA decision expected on February 25, 2026.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com